Joel Isaacson & Co., LLC Arvinas, Inc. Transaction History

Joel Isaacson & Co., LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 24, 2024	SELL	$14.19 - $42.33 $127,710 - $380,970	-9,000 Reduced 45.0%	11,000 $452,000
Q3 2023 Oct 23, 2023	SELL	$19.64 - $28.21 $68,740 - $98,735	-3,500 Reduced 14.89%	20,000 $392,000
Q2 2023 Jul 26, 2023	SELL	$21.73 - $31.43 $119,515 - $172,865	-5,500 Reduced 18.97%	23,500 $583,000
Q1 2023 Apr 24, 2023	SELL	$26.15 - $37.26 $26,150 - $37,260	-1,000 Reduced 3.33%	29,000 $792,000
Q4 2022 Jan 27, 2023	SELL	$32.47 - $57.24 $324,700 - $572,400	-10,000 Reduced 25.0%	30,000 $0
Q3 2022 Oct 13, 2022	BUY	$41.87 - $57.99 $795,530 - $1.1 Million	19,000 Added 90.48%	40,000 $1.78 Million
Q2 2022 Jul 15, 2022	SELL	$36.01 - $74.24 $144,040 - $296,960	-4,000 Reduced 16.0%	21,000 $884,000
Q1 2022 Apr 21, 2022	SELL	$60.27 - $81.57 $1.51 Million - $2.04 Million	-25,000 Reduced 50.0%	25,000 $1.62 Million
Q4 2021 Jan 19, 2022	SELL	$65.85 - $96.21 $1.46 Million - $2.13 Million	-22,156 Reduced 30.71%	50,000 $4.11 Million
Q3 2021 Oct 21, 2021	BUY	$73.2 - $107.87 $5.28 Million - $7.78 Million	72,156 New	72,156 $5.93 Million

229

68.4M

226K

285K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $1.02B
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Joel Isaacson & Co., LLC, based on Form 13F filings with the SEC.

Stay updated on Joel Isaacson & Co., LLC with notifications on news.